-
Under the rapid growth of the big health market, pharmaceutical machinery enterprises are actively laying out
Time of Update: 2022-10-12
). In addition, as a traditional pharmaceutical equipment enterprise, Qianyan Yam Machine has also been seeking transformation since 2014, and has launched a number of mergers and acquisitions and foreign investments in the fields of genetic testing, big health management, medical devices and other fields, and has successively set up a number of subsidiaries.
-
Over 18 billion yuan of market, a large number of domestic pharmaceutical companies are actively layout!
Time of Update: 2022-10-12
Recently, there have been reports that the FDA has approved Auvelity, a new drug developed by Axsome, for the treatment of Major Depressive Disorder (MDD) in adults.
-
Notice on the Public Solicitation of Opinions on the Guiding Principles for the Identification, Management and Evaluation of Drug-induced Liver Injury in Clinical Trials
Time of Update: 2022-10-12
docx for Solicitation of Comments Notice on the Public Solicitation of Opinions on the Guiding Principles for the Identification, Management and Evaluation of Drug-induced Liver Injury in Clinical Trials Release date: 20221008 To further guide the assessment of the potential for drug-induced liver injury in clinical trials of drugs, to ensure the safety of subjects, and to obtain safety information to assess the risk characteristics of the drug in the trial.
-
Progress in rare disease drug research in China
Time of Update: 2022-10-12
(See Figure 2 for details) Although the economic return is not the most cost-effective, the proportion of rare disease drug research and development in the world's leading pharmaceutical companies is relatively high.
-
Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Solicitation of Comments) Released
Time of Update: 2022-10-12
Transferred from: CDE Editor: On September 26, CDE publicly solicited opinions on the "Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Comments)" 。
-
A number of local API companies pass Jiayin, which is related to the approval of products and the construction of production capacity
Time of Update: 2022-10-12
Hokuriku Pharmaceutical announced on the evening of September 29 that recently, the company's repaglinide API received the "Notice of Approval of Chemical API Listing Application" issued by the State Food and Drug Administration.
-
Many places are accelerating the exploration of TCM medical insurance payment reform!
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Recently, Guangxi held a performance evaluation report meeting on the reform of medical insurance payment methods for the dominant diseases of traditional Chinese
-
In order to enhance competitiveness, pharmaceutical companies are vigorously building R&D production bases
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Recently, the "New Leading (Chongqing) Biomedical Integration R&D Service Base" project invested and built by Beijing New Leading Pharmaceutical Science and Technology Development Co.
-
The commercialization/R&D of innovative drugs is constantly achieving new breakthroughs, and it is recommended to pay attention to these companies
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】 Biomedical innovation is related to people's health, and the development of pharmaceutical industry is the fundamental embodiment and guarantee of the people's p
-
Novartis Pharmaceuticals: To be the top five pharmaceutical companies in the United States and the top three in China
Time of Update: 2022-10-12
Establish the China Center for Evidence-Based Medicine of Traditional Chinese Medicine, build a multi-dimensional evaluation technology system for proprietary Chinese medicines, carry out evidence-based evaluation of dominant diseases in traditional Chinese medicine, and provide guidance for the rational use of drugs in clinical practice.
-
The merger and acquisition of Kailai Ying and Zhongsheng Pharmaceutical have encountered obstacles one after another! Under the US New Deal, the internationalization of Chinese pharmaceutical companies needs real innovation!
Time of Update: 2022-10-12
On the evening of June 23, Zhongsheng Pharmaceutical announced that it had reached a merger agreement and plans to acquire all outstanding common shares of F-star, a NASDAQ-listed company, for a total consideration of $161 million, or $7.
-
The third quarterly report of the listed company is about to be disclosed, and the pharmaceutical company is expected to get the first attention
Time of Update: 2022-10-12
On September 19, Kaipu Bio released the first three quarters of 2022 performance forecast, during the reporting period, the net profit attributable to the shareholders of the listed company is expected to be 1.
-
Together for a long time! The road to the spin-off of multinational giants in 2022
Time of Update: 2022-10-12
In August, Novartis announced plans to 100% divest its generic and biosimilar division, Sandoz, into a newly listed independent operating company, with the spin-off process expected to be completed in the second half of next year.
-
Notice on the Public Solicitation of Opinions on the Technical Guidelines for the Pharmacological Research of New Medicinal Compounds of Traditional Chinese Medicines Based on Human Experience (Draft for Solicitation of Comments).
Time of Update: 2022-10-12
Drug Evaluation Center of the State Drug Administration September 27, 2022 Related Attachments serial number The attachment name 1 Technical Guidelines for the Pharmacological Research of New Pharmacognostics of Traditional Chinese Medicine Compound Preparations Based on Human Experience (Draft for Solicitation of Comments).
-
The new Pharmacopoeia Committee was established, and the preparation of the 2025 edition of the Chinese Pharmacopoeia was launched!
Time of Update: 2022-10-12
It is necessary to continuously improve the scientificity, advancedness, practicality and standardization of pharmacopoeia, and strengthen the guiding role of the Chinese Pharmacopoeia in ensuring the safety, effectiveness and quality control of drugs; Implement the concept of drug life cycle management, actively explore the development strategy of drug standards, give full play to the important technical support role of drug standards for drug supervision, and promote the improvement of regulatory capabilities.
-
Starting next month, the major pharmaceutical provinces will include a large number of traditional Chinese medicine formula granules in medical insurance
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Chinese medicine formula granules are an important part of traditional Chinese medicine, which is a "modern" product of traditional Chinese medicine, with the adv
-
Keji Pharmaceutical Announces 2022 Interim Results: Continue to Promote CAR-T Technology Innovation and Product Pipeline
Time of Update: 2022-10-06
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Keji Pharmaceuticals, an innovative CAR-T cell therapy company primarily focused on the treatment of hematological malignancies and solid tumors, has announced
-
Guiding opinions on further promoting the development of the integration of medical and nursing care
Time of Update: 2022-10-06
All relevant departments in all localities should adhere to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, conscientiously implement the decision-making and deployment of the Party Central Committee and the State Council, further improve policies and measures, focus on solving difficult problems and blockages, promote the development of medical and nursing care, and continuously meet the needs of health and old-age services for the elderly.
-
The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use
Time of Update: 2022-10-06
BEIJING, Aug. 24, 2022 /PRNewswire/ -- Nuocheng Jianhua and Connoya jointly announced today that they have received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration The CCR8-targeting monoclonal antibody CM369 developed by Nuojiancheng has carried out clinical trials in advanced solid tumors .
-
2022 Biological Fermentation Exhibition - Brand enterprises have settled in to seize the opportunity, who comes to the feast
Time of Update: 2022-10-03
The 10th Shanghai Biological Fermentation Products & Technology Equipment Exhibition (hereinafter referred to as BIO CHINA 2022) will be held on December 1-3, 2022 at Shanghai New International Expo Center.
